PAR 16 CO-PAYMENTS IN RHEUMATOID ARTHRITIS OBSERVED IN A GERMAN COHORT  by Mittendorf, T et al.
665Abstracts
were retired prematurely due to RA-related work disability and
incurred costs of 8358€ per retired patient-year. Ninety-six
patients were gainfully employed and incurred sick leave costs
of 2835€ per employed patient-year. CONCLUSIONS: Micro-
costing based on health care payer’s data provides a relatively
conservative albeit highly accurate estimate of costs in RA. It is
important to take both RA-related and non-RA-related costs into
account. Medication costs are the dominant direct component
with an increase due to the introduction of biologic agents. In
gainfully employed patients and in patients who receive RA-
related retirement payments productivity costs exceed direct
costs.
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OBJECTIVE: Rheumatoid Arthritis (RA) is a disease with high
socioeconomic impact. Anti-TNF drugs have provided evidence
of effectiveness in treating RA patients resistant to 2 previous
conventional DMARDs, including MTX, as demonstrated by a
number-needed-to-treat (NNT) of 2 to produce a 20% improve-
ment in American College of Rheumatology (ACR) score
(ACR20). Anti-TNF therapy is also costly. The aim of this 
retrospective longitudinal cost of care analysis was to evaluate
the cost of Etanercept (ETA) vs Inﬂiximab (IFX) used at the 
standard dosage (according to the ANTARES Protocol) for the
treatment of RA patients after DMARDs (disease-modifying
anti-rheumatic drugs) failure in Italy. METHODS: The study
included subjects randomly enrolled from 7 centres participating
to a prospective data collection program called ANTARES.
Direct health care resources attributable to RA management
(drugs, ambulatory care, day case treatments, hospitalizations)
were quantiﬁed using National Health Service (NHS) tariffs
expressed in Euro 2003. NHS perspective was adopted. Multi-
ple linear regression techniques were used to investigate differ-
ences between IFX and ETA in the direct cost, adjusting for sex,
age, baseline ESR (erythrocyte sedimentation rate), baseline DAS
(disease activity score) and centre. RESULTS: A total of 211 (IFX
101, ETA 110) patients affected by RA (F/M 165/46; mean age
50.7 ± 14.5 years old) were studied. Mean total annual direct
costs for RA patients were euro 16,988 (±7245). The regression
analysis showed that adjusting for sex, baseline ESR, age, base-
line DAS and centres total direct costs per patient in ETA group
were 3427 Euro lower than in IFX patients (P < 0.0001). CON-
CLUSIONS: The total direct cost of Etanercept is statistically sig-
niﬁcantly lower than Inﬂiximab, when the drug are used at the
standard dosage, according to the ANTARES Protocol.
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OBJECTIVES: The aim was to focus on the ﬁnancial burden of
co-payments for patients with rheumatoid arthritis under new
German law regulations. METHODS: The assessment of all cost
data was part of a clinical multicenter randomized RA-trial in
Germany. For 136 RA-patients (1987 ACR criteria, mean age
57.4 (±12.5) years, mean disease duration 8.2 (±8.4) years, 77%
females) every 3 months corresponding cost data were derived
from 1) a RA-related patient-centered health economic ques-
tionnaire, and 2) the payer’s database (insurance and physicians’
association) over a period of 18 months. Co-payments in
Germany partly can be derived by analyzing the payers’ data due
to speciﬁc legal regulations. In addition to that patient-derived
data was evaluated. RESULTS: The data was composed in a
matrix of different cost domains. Those led to patient co-
payments/ year of 417.10€. Visits to a physician accounted for
9.2% (38.40€), non-physician service utilization for 46.6%
(194.40€), medication for 23.7% (99€), hospital co-payments
for 5.8% (24€), transportation for 13.5% (56.20€), and devices
and aids for 1.2% (5.10€) of the overall co-payment costs. CON-
CLUSIONS: The impact of co-payments on patients with
chronic diseases needs to be addressed by policy makers. Even
in an environment with relatively low co-payment regulations
like Germany the burden for RA-patients can become substan-
tial.
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OBJETIVES: ARTS is a self reported instrument designed to
measure four treatment satisfaction dimensions: Treatment
advantages, Treatment convenience, Apprehension about treat-
ment and Satisfaction with medical care; and is composed by 18
Likert-scale items. It is intended to be used with patients suffer-
ing osteoarthritis and undergoing oral administered treatments.
METHODS: Linguistic adaptation was performed using the
standard processes for establishing conceptual equivalence. A
panel of six experts supervised the process and four independent
translators translated and back-translated the items. A sample of
163 patients was used to gauge psychometric properties. All
patients suffered from knee, hip or column arthritis. Patients
were included in 3 groups: treatment-switch because of a weak
analgesic effect, treatment-switch due to poor tolerability and
no-change. The ARTS was administered at baseline, 1 week later
and after 4 weeks of therapy with traditional NSAIDs or Cox II-
inhibitors. RESULTS: Mean age was 67.7 ± 9.2 years old. The
adapted instrument showed good feasibility and reliability prop-
erties. No ﬂoor or ceiling effects where found, items where well
understood and non-response rates were below one percent
(1%). Cronbach’s alpha for the total scales was 0.85. Instrument
was stable with a test-retest intraclass correlation coefﬁcient of
0.83. Exploratory factor analysis yielded four dimensions coher-
ent with those proposed by the original authors. Convergent
validity was measured against SF-36, a pain VAS a treatment
compliance VAS, and Morisky-Green compliance questionnaire.
The adapted instrument showed good discriminant validity,
being able to distinguish between patients needing a change in
